At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09926 AKESO
Trading 12-23 13:41:46
59.100
-1.750
-2.88%
High61.100Low57.950Vol6.71M
Open60.850D1 Closing60.850Amplitude5.18%
Mkt Cap53.07BTradable Cap53.07BTotal Shares898.00M
T/O395.40MT/O Rate0.75%Tradable Shares898.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
GF Securities Starts Akeso at Buy with HK$81.59 Price Target
MT Newswires Live  ·  12-11
GF Securities Starts Akeso at Buy with HK$81.59 Price Target
Akeso's Cervical Cancer Drug Included in China's National Reimbursement Drug List
MT Newswires Live  ·  11-28
Akeso's Cervical Cancer Drug Included in China's National Reimbursement Drug List
BRIEF-Akeso's Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA
Reuters  ·  11-22
BRIEF-Akeso's Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA
Akeso's Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma Accepted by Nmpa
THOMSON REUTERS  ·  11-22
Akeso's Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma Accepted by Nmpa
HK's Stock Benchmark Quarterly Review May Add Kuaishou, Pop Mart Stocks
Bloomberg  ·  11-22
HK's Stock Benchmark Quarterly Review May Add Kuaishou, Pop Mart Stocks
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab
THOMSON REUTERS  ·  11-01
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined With Ligufalimab (Cd47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (Hnscc), Compared to Pembrolizumab
THOMSON REUTERS  ·  10-31
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined With Ligufalimab (Cd47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (Hnscc), Compared to Pembrolizumab
Akeso Raises HK$1.92 Through Share Placement
MT Newswires Live  ·  10-22
Akeso Raises HK$1.92 Through Share Placement
Igcs Late Breaking Abstract and the Lancet: Akeso Published Positive Pfs and Os Results From Phase 3 First-Line Study of Cadonilimab in Cervical Cancer
THOMSON REUTERS  ·  10-16
Igcs Late Breaking Abstract and the Lancet: Akeso Published Positive Pfs and Os Results From Phase 3 First-Line Study of Cadonilimab in Cervical Cancer
Stock Track | AKESO Shares Tumble 5.35% on $1.92 Billion Share Placement Plans
Stock Track  ·  10-14
Stock Track | AKESO Shares Tumble 5.35% on $1.92 Billion Share Placement Plans
Stock Track | Akeso Shares Tumble 5.35% After Announcing $1.92 Billion Share Placement
Stock Track  ·  10-14
Stock Track | Akeso Shares Tumble 5.35% After Announcing $1.92 Billion Share Placement
Akeso to Raise HK$1.92 Billion from Share Placement
MT Newswires Live  ·  10-14
Akeso to Raise HK$1.92 Billion from Share Placement
Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline
THOMSON REUTERS  ·  10-13
Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline
Akeso First Half 2024 Earnings: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)
Simply Wall St.  ·  10-02
Akeso First Half 2024 Earnings: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)
Akeso's Immunotherapy Drug Gets Full Certificate from NMPA
MT Newswires Live  ·  10-01
Akeso's Immunotherapy Drug Gets Full Certificate from NMPA
Akeso's New Drug Application for Cholesterol Drug Receives OK from NMPA
MT Newswires Live  ·  10-01
Akeso's New Drug Application for Cholesterol Drug Receives OK from NMPA
BRIEF-Akeso Says NMPA Approved SNDA Of (Cadonilimab, Pd-1/Ctla-4) In Combination With Chemotherapy
Reuters  ·  09-30
BRIEF-Akeso Says NMPA Approved SNDA Of (Cadonilimab, Pd-1/Ctla-4) In Combination With Chemotherapy
Akeso - Nmpa Approved New Drug Application of Ebronucimab, Pcsk9
THOMSON REUTERS  ·  09-30
Akeso - Nmpa Approved New Drug Application of Ebronucimab, Pcsk9
Akeso - Nmpa Approved Snda of ® (Cadonilimab, Pd-1/Ctla-4) in Combination With Chemotherapy
THOMSON REUTERS  ·  09-30
Akeso - Nmpa Approved Snda of ® (Cadonilimab, Pd-1/Ctla-4) in Combination With Chemotherapy
Akeso's Cadonilimab Receives Second Indication Approval From Nmpa for First-Line Treatment of Gastric/Gej Cancer in All-Comers Population
THOMSON REUTERS  ·  09-30
Akeso's Cadonilimab Receives Second Indication Approval From Nmpa for First-Line Treatment of Gastric/Gej Cancer in All-Comers Population

Introduction

Company Name.
AKESO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.
Issue price:
--